We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App





Siemens Introduces New Intelligent, Integrated IVD Solutions Virtually at EUROMEDLAB 2021

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)
Image: Atellica Solution (Photo courtesy of Siemens Healthineers)

Siemens Healthineers (Erlangen, Germany) introduced new intelligent, integrated IVD solutions virtually at the XXIV IFCCEFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab Congress 2021).

EuroMedLab Congress 2021 was to be held as an in-presence meeting between 28th of November and 2nd of December in Germany but was postponed after the country was hit very hard by a fourth wave of COVID-19. However, those interested participated virtually in the Siemens EUROMEDLAB Experience that showcased its latest innovations. Siemens offered a virtual booth tour, held product demonstrations, and hosted expert presentations and on-demand webinars.

At its virtual booth, Siemens demonstrated its Atellica Solution comprising flexible, scalable, automation-ready immunoassay and chemistry analyzers with integrated automation. The company also highlighted of its extensive Atellica portfolio of tests that deliver accurate, clinically relevant results, including SARS-CoV-2 antibody tests, COVID-19 antigen assay, Atellica IM B·R·A·H·M·S PCT Assay for early sepsis risk assessment, and proven, true high-sensitivity cardiac troponin I assays for managing chest pain patients. Siemens highlighted the Atellica CI 1900 System which is being developed for the lower-to-mid-volume laboratories. It is planned to utilize the same menu, reagents, consumables, and detection technology as the Atellica Solution. Siemens also demonstrated how its Atellica Diagnostics IT can help labs unify data and optimize workflow with simple, open, and scalable solutions.

Siemens held virtual product demonstrations of its new Atellica Hematology Portfolio which pairs automation, intelligence, and extended parameters to streamline operations and support accurate clinical decision-making. The company presented the Sysmex CN-3000 and CN-6000 fully automated, mid-and high-volume coagulation analyzers which combine size, speed, intelligence, and flexibility.

In addition, Siemens virtually demonstrated its epoc blood analysis system, a handheld, wireless solution to enable comprehensive blood analysis testing at the patient’s side on a single room temperature test card, with results in less than a minute. Visitors to its virtual booth also saw the DCA Vantage Analyzer that helps monitor glycemic control and detect early kidney disease in environments ranging from the physician’s office to remote, point-of-care coordinated sites in hospitals and multisite practices. Among other products, Siemens virtually demonstrated rapid clinical decision-making with lab-comparable results from its broad POC blood gas portfolio, its high-sensitivity troponin I testing solution, and the new Sysmex CN-3000 and CN-6000 Systems for accelerating hemostasis workflows.

Related Links:
Siemens Healthineers 

Gold Supplier
Molecular Diagnostic System
iPonatic
New
UV/Vis Spectrophotometer
BioDrop DUO+
New
High Throughput Electrolyte Analyzer
CBS-50
New
3-Part Diff Auto Hematology Analyzer
Cellagon 3

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Illustration

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.